Edgewise Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $2,252 | $0 |
Gross Profit | -534 | -525 | 1,719 | -448 |
EBITDA | -37,573 | -34,228 | -33,329 | -29,452 |
EBIT | -38,107 | -34,753 | -33,862 | -29,900 |
Net Income | -31,497 | -28,525 | -30,143 | -25,713 |
Net Change In Cash | 0 | 0 | 2,252 | 0 |
Free Cash Flow | -26,320 | -28,895 | -26,991 | -22,515 |
Cash | 43,485 | 30,264 | 86,097 | 32,957 |
Basic Shares | 93,515 | 87,567 | 64,774 | 63,459 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1,732 | -538 | -272 | -185 |
EBITDA | -112,806 | -21,541 | -42,943 | -17,007 |
EBIT | -114,357 | -22,079 | -43,215 | -17,192 |
Net Income | -100,163 | -15,397 | -42,139 | -17,054 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 6,427 | -89,350 | ||
Free Cash Flow | -97,693 | -58,181 | -34,175 | -14,837 |
Cash | 86,097 | 351,947 | 280,789 | 104,916 |
Basic Shares | 63,723 | 53,593 | 49,500 | 49,217 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.34 |
2024-03-31 | -$0.33 |
2023-12-31 | -$0.47 |
2023-09-30 | -$0.41 |
